Poliovirus type 1 antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Ipol, Kinrix, Pediarix, Pentacel, Quadracel, Vaxelis
Generic Name
Poliovirus type 1 antigen (formaldehyde inactivated)
DrugBank Accession Number
DB10795
Background

Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Inactivated poliomyelitis vaccine (V.C.O.) type 1 Mahoney
  • Inactivated poliovirus type I
  • poliovirus vaccine inactivated, type 1 (Mahoney)

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ADACEL POLIO 0,5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETPoliovirus type 1 antigen (formaldehyde inactivated) (40 DU/5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 mcg/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg/0.5mL) + Bordetella pertussis pertactin antigen (3 mcg/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (2.5 mcg/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 Lf/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 Lf/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/5mL)Injection, suspensionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag
BOOSTRIX POLIO 0,5 ML IM ENJEKSIYON ICIN SUSPANSIYON ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADETPoliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 mcg/0.5ml) + Bordetella pertussis pertactin antigen (2.5 mcg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 mcg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (20 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 IU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)SuspensionIntramuscularGLAXOSMİTHKLİNE İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
HexacimaPoliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Haemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaPoliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Haemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaPoliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Haemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaPoliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Haemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaPoliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Haemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaPoliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Haemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaPoliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Haemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HEXAXIMPoliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU/0.5ml) + Haemophilus influenzae b polysaccharide-tetanus conjugate (12 mcg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 mcg/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5ml)Injection, suspensionIntramuscularบริษัท ซาโนฟี่ ปาสเตอร์ จำกัด2017-05-31Not applicableThailand flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
0LVY784C09
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910901
RxNav
763096

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Poliomyelitis / Tetanus1
4CompletedPreventionAcellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B1
4CompletedPreventionDiphtheria / Haemophilus Infections / Pertussis / Poliomyelitis / Tetanus1
4CompletedPreventionDiphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus1
4CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Pertussis / Poliomyelitis / Tetanus1
4CompletedPreventionDiphtheria / Pertussis / Poliomyelitis / Tetanus3
4CompletedPreventionDrug Therapy, Combination / Fever, Chemically Induced / Infants / Vaccines, Pneumococcal1
4CompletedPreventionFlu caused by Influenza1
4CompletedPreventionPertussis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular
SuspensionSubcutaneous
Injection
SuspensionIntramuscular
Injection, powder, for suspensionIntramuscular
Injection, suspensionIntramuscular
InjectionIntramuscular
Injection, suspensionIntramuscular; Subcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:04 / Updated on June 12, 2020 16:53